Patent Law Weblog
Month: May 2007
-
By Donald Zuhn — On Thursday, the California Healthcare Institute (CHI), an independent organization comprising more than 250 biomedical companies, academic and research institutions, and companies involved in supporting the biomedical community, released a white paper entitled "Impact of Patent Law Changes on Biomedical Investment and Innovation." The CHI white paper analyzes the…
-
By Kevin E. Noonan — One of the many benefits touted by proponents of the Human Genome Project has been the prospect of personalized medicine, based on a determination of an individual’s entire genomic DNA sequence. The advantages of this information are expected to include an understanding about the status of disease propensity-associated…
-
By Christopher P. Singer — In a May 29, 2007 press release, sanofi-aventis and UCB announced that the FDA approved Xyzal® (active ingredient: levocetirizine dihydrochloride) a once-daily prescription antihistamine for the relief of seasonal and perennial allergic rhinitis, as well as for the treatment of chronic idiopathic urticaria (hives) in adults and in…
-
By Donald Zuhn — On Tuesday, Invitrogen Corporation and Clontech Laboratories, Inc. jointly announced that the two companies had reached a settlement in a patent litigation battle that had been begun more than 11 years earlier. Invitrogen had initiated the lawsuit when it filed a complaint against Clontech in December of 1996 in…
-
By Jason Derry — Novacea, Inc. and Schering-Plough have announced an agreement to develop and commercialize Asentar®, which is currently in Phase III clinical trials for the treatment of prostate cancer. Novacea is to receive an upfront payment of $60 million and $12 million in common stock. Novacea may also receive up to…
-
By Kevin E. Noonan — There are new developments in global drug pricing policy today, but while they are good news for sub-Saharan Africa they fall far short of addressing the overarching disaster facing Western drug companies in these disputes (see "Worldwide Drug Pricing Regime in Chaos"). In a move kindly described as…
-
American Conference Institute (ACI) will be holding a conference on Pharma and Biotech Collaborative Agreements on July 16-17, 2007 in San Francisco, CA. The conference will provide information about protecting intellectual property rights, minimizing risks through effective due diligence, developing effective governance processes, drafting termination provisions, overcoming antitrust violations, anticipating the impact of generics, and…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Allergan Inc. v. Apotex Inc. et. al.1:07-cv-00278; filed May 21, 2007 in the District Court of Delaware Infringement of U.S. Patent Nos.…
-
By Kevin E. Noonan — The significance of single nucleotide polymorphisms (SNPs) has been appreciated in genetic research ever since the discovery in the early 1980’s that SNPs could produce genetic markers known as restriction fragment length polymorphisms (RFLPs). However, although this type of polymorphism is responsible for well-recognized genetic mutations (for example,…
-
May 30, 2007 – "Patent Law After KSR v. Teleflex: Are Your Patents Still Valid?" (ABA CLE) May 30, 2007 – "Stating the Obvious: Patent Protection after KSR" (Managing Intellectual Property) May 31, 2007 – "Biotechnology and the Law: A Primer" – Part I (ABA CLE) May 31, 2007 – "KSR International Co. v. Teleflex…
Patent Docs 